Your browser doesn't support javascript.
loading
Treatment strategies and responses for attacks of neuromyelitis optica spectrum disorder: A real-world retrospective cohort study.
Carnero Contentti, Edgar; Lopez, Pablo A; Pettinicchi, Juan Pablo; Miguez, Jimena; Patrucco, Liliana; Cristiano, Edgardo; Liwacki, Susana; Tkachuk, Verónica; Balbuena, María E; Vrech, Carlos; Deri, Norma; Correale, Jorge; Marrodan, Mariano; Ysrraelit, María C; Leguizamon, Felisa; Luetic, Geraldine; Tavolini, Darío; Mainella, Carolina; Zanga, Gisela; Burgos, Marcos; Hryb, Javier; Barboza, Andrés; Lazaro, Luciana; Alonso, Ricardo; Fernández Liguori, Nora; Nadur, Débora; Alonso Serena, Marina; Caride, Alejandro; Rojas, Juan I.
Afiliação
  • Carnero Contentti E; Neuroimmunology Unit, Department of Neurosciences, Hospital Alemán, Buenos Aires, Argentina. Electronic address: junior.carnero@hotmail.com.
  • Lopez PA; Neuroimmunology Unit, Department of Neurosciences, Hospital Alemán, Buenos Aires, Argentina.
  • Pettinicchi JP; Neuroimmunology Unit, Department of Neurosciences, Hospital Alemán, Buenos Aires, Argentina.
  • Miguez J; Servicio de Neurología, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina.
  • Patrucco L; Centro de esclerosis múltiple de Buenos Aires, Buenos Aires, Argentina.
  • Cristiano E; Centro de esclerosis múltiple de Buenos Aires, Buenos Aires, Argentina.
  • Liwacki S; Clínica Universitaria Reina Fabiola, Córdoba, Argentina; Servicio de Neurología - Hospital Córdoba, Córdoba.
  • Tkachuk V; Sección de Neuroinmunología y Enfermedades Desmielinizantes, Servicio de Neurología - Hospital de Clínicas José de San Martín, Buenos Aires, Argentina.
  • Balbuena ME; Sección de Neuroinmunología y Enfermedades Desmielinizantes, Servicio de Neurología - Hospital de Clínicas José de San Martín, Buenos Aires, Argentina.
  • Vrech C; Departamento de Enfermedades desmielinizantes - Sanatorio Allende, Córdoba, Argentina.
  • Deri N; CENyR, Buenos Aires, Argentina.
  • Correale J; Departamento de Neurología - FLENI, Buenos Aires, Argentina.
  • Marrodan M; Departamento de Neurología - FLENI, Buenos Aires, Argentina.
  • Ysrraelit MC; Departamento de Neurología - FLENI, Buenos Aires, Argentina.
  • Leguizamon F; Hospital de Agudos, Dr. Teodoro Álvarez, Buenos Aires, Argentina.
  • Luetic G; Instituto de Neurociencias de Rosario, Santa Fe, Argentina.
  • Tavolini D; INECO Neurociencias Oroño, Rosario, Santa Fe, Argentina.
  • Mainella C; Hospital Español de Rosario, Santa Fe, Argentina.
  • Zanga G; Unidad asistencial César Milstein, Buenos Aires, Argentina.
  • Burgos M; Servicio de Neurología - Hospital San Bernardo, Salta, Argentina.
  • Hryb J; Servicio de Neurología - Hospital Carlos G. Durand, Buenos Aires, Argentina.
  • Barboza A; Hospital Central de Mendoza, Mendoza, Argentina.
  • Lazaro L; Sanatorio Güemes, Buenos Aires, Argentina.
  • Alonso R; Sanatorio Güemes, Buenos Aires, Argentina.
  • Fernández Liguori N; Sanatorio Güemes, Buenos Aires, Argentina.
  • Nadur D; Sección de Neuroinmunología y Enfermedades Desmielinizantes, Servicio de Neurología - Hospital de Clínicas José de San Martín, Buenos Aires, Argentina; Hospital Naval, Buenos Aires, Argentina.
  • Alonso Serena M; Servicio de clínica médica, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina.
  • Caride A; Neuroimmunology Unit, Department of Neurosciences, Hospital Alemán, Buenos Aires, Argentina.
  • Rojas JI; Centro de esclerosis múltiple de Buenos Aires, Buenos Aires, Argentina; Servicio de Neurología, Hospital Universitario de CEMIC, Buenos Aires, Argentina.
J Neurol Sci ; 462: 123099, 2024 Jul 15.
Article em En | MEDLINE | ID: mdl-38897155
ABSTRACT
We aimed to assess the treatment strategies utilized in patients with neuromyelitis optica spectrum disorder (NMOSD) experiencing relapses, including their frequency, types, and response after 6 months based on the Expanded Disability Status Scale (EDSS) score.

METHODS:

We conducted a retrospective study involving NMOSD patients from the Argentinean MS and NMOSD registry (RelevarEM, NCT03375177). Treatment response at 6 months was categorized as "good" if the EDSS score decreased by ≥1 point after a nadir EDSS score ≤ 3, or by ≥2 points after a nadir EDSS score > 3, "poor" if the EDSS score decrease was slighter, and as "absent" if the EDSS score remained unchanged or worsened.

RESULTS:

We included 120 NMOSD patients (seropositive N = 75), who experienced 250 NMOSD-related relapses and received 248 treatments. At 6 months, complete recovery was achieved in 70/98 (71.4%) and 15/19 (79%) patients, respectively. Predictors of a "good" response in our regression model were a younger age at disease onset (OR3.54, CI95% 2.45-5.01, p < 0.0001) and a short delay from onset of relapse to treatment initiation (OR1.56, CI95% 1.22-2.13, p = 0.004).

CONCLUSIONS:

Approximately two-thirds of patients experienced complete recovery, and younger age and a short delay to start treatment were independent predictors of a "good" response.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neuromielite Óptica Limite: Adult / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neuromielite Óptica Limite: Adult / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2024 Tipo de documento: Article